Loading clinical trials...

COMPLETEDPHASE2

Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms

Evaluation of the Incidence and Prognostic Impact of Molecular and Genetic Abnormalities in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myeloproliferative Neoplasms

NCT02084563•Hospital Israelita Albert Einstein

View on ClinicalTrials.gov

Summary

The objective of this study is to describe the prevalence and prognostic impact of the most common genetic abnormalities in patients with Myeloid Neoplasms, including Acute Myeloid Leukemia (AML), Myeloproliferative Neoplasms (MPN), Myelodysplastic Syndromes (MDS) and Myeloproliferative/Myelodysplastic Neoplasms. Patients will have samples of blood and/or bone marrow collected and sent to Hospital Israelita Albert Einstein for analysis and storage. Patients with a diagnosis of Acute Myeloid Leukemia will be treated according to an uniform protocol.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Acute Myeloid Leukemia-Intensive Chemotherapy
•Diagnosis of AML according to WHO criteria
•Age greater than 18 years
•Performance status (ECOG) between 0-2
•Adequate liver and kidney function
•Signed Informed Consent form
•No prior therapy for AML, except use of hydroxyurea for control of elevated white blood cell counts
•Adequate contraception for fertile men and women
•Eligible for intensive chemotherapy (as judged by the treating physician)
•Diagnosis of AML according to WHO criteria
+8 more criteria

Exclusion Criteria

•Acute myeloid leukemia with retinoic acid receptor alpha (RARA) translocations (APL, acute promyelocytic leukemia)
•Pregnant women
•HIV-positivity
•New York Heart Association class III and IV congestive heart failure
•Patient refuses to use adequate contraception
•History of hypersensibility to any of the used chemotherapy drugs
•Patient refuses to sign informed consent form
•Acute Myeloid Leukemia-Non-Intensive Chemotherapy
•Acute myeloid leukemia with RARA translocations (APL, acute promyelocytic leukemia)
•Pregnant women
+6 more criteria

Locations (1)

Hospital Israelita Albert Einstein

São Paulo, São Paulo, Brazil

Key Dates

Start Date

October 1, 2012

Primary Completion Date

December 1, 2014

Completion Date

November 1, 2016

Last Updated

November 8, 2016

Enrollment

455

ACTUAL participants

Conditions

Acute Myeloid LeukemiaMyeloproliferative NeoplasmsMyelodysplastic SyndromesMyeloproliferative/Myelodysplastic Neoplasm

Interventions

Induction Chemotherapy

DRUG

Consolidation Chemotherapy

DRUG

Autologous Stem Cell Transplantation

DRUG

Allogeneic Stem Cell Transplantation

DRUG

Low Dose Cytarabine

DRUG

Decitabine

DRUG

Phase I Study of HC-7366 for Acute Myeloid Leukemia

NCT06285890

Acute Myeloid Leukemia

View study

RECRUITINGPHASE2

VAC Regimen for AML Patients Who Failed to Response to VA Regimen

NCT06220162

Acute Myeloid Leukemia

View study

RECRUITINGPHASE1/PHASE2

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

NCT04065399

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 8, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms

Inclusion Criteria

Exclusion Criteria

Phase I Study of HC-7366 for Acute Myeloid Leukemia

VAC Regimen for AML Patients Who Failed to Response to VA Regimen

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias